BPC-157 vs Cerebrolysin
Body Protection Compound · Neurotrophic Peptide Mixture
Here is how these two compounds compare, based on published research, not marketing claims.
BPC-157
A tissue repair peptide that promotes blood vessel formation and growth factor signaling at injury sites; over 200 published studies, predominantly animal models.
Cerebrolysin
A neuropeptide preparation that delivers brain-repair signals across the blood-brain barrier; approved in 40+ countries for stroke recovery, TBI, and dementia.
BPC-157
212 studies
4 human trials
Not FDA-Approved
Cerebrolysin
658 studies
52 human trials
Not FDA-Approved
What it does
BPC-157
In animal studies, drives new blood vessel formation at injury sites, one of the body's main repair signals in damaged tissue. A short peptide fragment originally isolated from human stomach juice that, in rodent models, ramps up production of growth factors involved in healing (VEGF, EGF, FGF). The angiogenic effect documented in those animal studies is what underlies the recovery claims that made BPC-157 prominent in athletic and post-surgical contexts. Published human evidence remains essentially absent.
Cerebrolysin
Delivers brain-repair signals into tissue that the bloodstream normally cannot reach. Made of short peptide fragments derived from pig brain tissue, small enough to cross the blood-brain barrier.
How it works
BPC-157
A copy of a small protein the body naturally makes in the stomach. It works by turning up three repair signals (VEGF, EGF, FGF) that tell the body to build new blood vessels. It also nudges the nitric oxide system, which controls blood flow and inflammation. In animal research, the result is the body's own repair process running faster.
Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids produced by enzymatic breakdown of purified porcine brain proteins. The peptide fragments are small enough to cross the blood-brain barrier and mimic the activity of naturally occurring neurotrophic factors (BDNF, NGF, CNTF). Once in brain tissue, the fragments promote neuronal survival, stimulate synaptic plasticity, and support axonal growth and repair. The multi-target mechanism is the defining pharmacological feature: rather than hitting one receptor, cerebrolysin modulates several neuroprotective and neurorestorative pathways simultaneously.
How often
BPC-157
In studies, given as a daily shot under the skin, usually for several weeks at a time. Some studies have looked at oral forms specifically for gut work.
Cerebrolysin
Intravenous or intramuscular injection in clinical protocols across 40+ countries where cerebrolysin is approved. Published trials use multi-week treatment courses. Cerebrolysin is not FDA-approved in the United States; clinical availability in the U.S. does not exist through standard channels.
How strong
BPC-157
Local. The action concentrates at the injury rather than spreading body-wide.
Cerebrolysin
Approved in more than 40 countries for stroke recovery, traumatic brain injury, and various forms of dementia. Large-scale clinical trials in stroke rehabilitation (CASTA, CARS) showed functional recovery benefits. The evidence base includes over 200 published studies with more than 50 human clinical trials. The strongest data is in acute ischemic stroke recovery and post-TBI rehabilitation, where multiple independent research groups have replicated findings.
Main tradeoff
BPC-157
Strong animal data on tendons and gut healing. Human studies are thin. And one quirk: most of the published research traces back to a single research group, which limits how independent the findings are.
Cerebrolysin
Internationally approved with decades of clinical use in stroke and TBI rehabilitation across more than 40 countries. Not FDA-approved in the United States; the specific U.S. trial package the FDA requires was never completed despite international clinical evidence. The 2013 Cochrane review found the evidence insufficient to draw definitive conclusions about efficacy in dementia, though subsequent trials have added data. Injectable-only delivery limits accessibility. As a porcine-derived biological product, batch-to-batch consistency and standardization are more complex than for synthetic peptides.
Best for
BPC-157
- Research on a specific local injury: tendons, ligaments, or gut lining
- Research targeting one site rather than a body-wide effect
- Research using daily subcutaneous injection
Cerebrolysin
- Research interest in neuropeptide-based neuroprotection and neuroregeneration
- Research focused on stroke recovery, traumatic brain injury rehabilitation, or dementia where international clinical trial data applies
- Research comparing multi-target neuropeptide preparations versus single-target nootropic compounds
How to choose
A good fit for BPC-157
- Research on peripheral tissue injury: tendons, ligaments, gut lining, wound healing
- Research targeting local repair mechanisms at a specific injury site
- Research contexts where the injury is outside the central nervous system
A good fit for Cerebrolysin
- Research on cognitive impairment, stroke recovery, or traumatic brain injury
- Research targeting neuroprotection and neuroregeneration in brain tissue
- Research contexts where international clinical trial data in neurological populations is relevant
Consider both across time
BPC-157 and cerebrolysin operate in fundamentally different tissue domains. BPC-157 targets peripheral tissue repair through local growth factor signaling. Cerebrolysin targets brain tissue through neurotrophic factor mimicry after crossing the blood-brain barrier. They are not interchangeable; the comparison exists because both appear in research protocols as tissue-repair-adjacent compounds, but they serve entirely different anatomical targets.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Tissue Repair
- Tissue Repair connects to NO System Modulation
- NO System Modulation upregulates VEGF / EGF / FGF
- VEGF / EGF / FGF connects to Blood Vessel Formation
- Blood Vessel Formation connects to Nutrient Delivery
- Blood-Brain Barrier Crossing
- Blood-Brain Barrier Crossing enables Neurotrophic Factor Mimicry
- Neurotrophic Factor Mimicry connects to Neuronal Survival
- Neurotrophic Factor Mimicry connects to Synaptic Plasticity
- Neurotrophic Factor Mimicry connects to Axonal Growth and Repair
- Neuronal Survival connects to Cognitive and Functional Recovery; Synaptic Plasticity connects to Cognitive and Functional Recovery; Axonal Growth and Repair connects to Cognitive and Functional Recovery
BPC-157 increases growth factors (VEGF, EGF, FGF) that signal the body to build new blood vessels at the injury site.
Cerebrolysin's peptide fragments cross the blood-brain barrier to mimic neurotrophic factors that promote neuronal survival, synaptic plasticity, and axonal growth.
Research Evidence
Cerebrolysin has the dramatically deeper human evidence base: multiple randomized controlled trials across stroke, TBI, and dementia, regulatory approval in 40+ countries, and decades of clinical use. BPC-157 has broader preclinical tissue-type coverage but only two human pilot trials. The evidence gap in human data is substantial; cerebrolysin has international regulatory approval while BPC-157 remains entirely preclinical in regulatory terms. For peripheral tissue repair research, BPC-157 has relevant preclinical depth. For neurological research, cerebrolysin has the deeper clinical position.
- 1.
For neurological conditions (stroke, TBI, dementia), cerebrolysin has extensive clinical data.
- 2.
For tissue repair (tendon, gut, muscle), BPC-157 has more relevant research.
- 3.
For neuroprotection specifically, cerebrolysin is the established option.
- 4.
They are not interchangeable, different organ systems, different applications.
Key Limitations
- •No head-to-head comparison.
- •They target different organ systems, limiting direct comparison.
- •BPC-157's neuroprotective data is preliminary compared to cerebrolysin's.
- •Cerebrolysin's multi-component nature makes precise mechanistic comparison difficult.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
BPC-157
"BPC-157 healed my gut issues in two weeks"
Plausible but unproven in humans
"BPC-157 fixed my tendon injury faster than anything"
Plausible but unproven in humans
"BPC-157 is completely safe with no side effects"
Insufficient evidence
Cerebrolysin
"Cerebrolysin is used in hospitals across Europe and Asia"
Supported by evidence
"Cerebrolysin improved my cognitive function after brain injury"
Plausible (clinical data exists)
Safety Comparison
Cerebrolysin has the stronger safety record: decades of international clinical use with well-characterized adverse event profiles. BPC-157 has favorable animal safety data with no serious adverse events in the available human pilot data, but the human safety characterization is far less mature. As a porcine-derived biological product, cerebrolysin's batch-to-batch consistency and standardization are more complex than for synthetic peptides like BPC-157. Neither is FDA-approved in the United States.
BPC-157
Extensive animal safety data. Two human pilot studies. Not FDA-approved.
Cerebrolysin
Approved in 40+ countries. Extensive clinical safety data from multiple trials. Generally well-tolerated. IV and IM administration.
What the Research Suggests
Different specialties. BPC-157 for body repair. Cerebrolysin for brain repair. Comparing them is useful only for understanding which tool serves which goal.